吉非替尼联合放化疗对EGFR突变型非小细胞肺癌患者的效果

Effects of Gefitinib combined with chemoradiotherapy on patients with EGFR mutant non-small cell lung cancer

目的:观察吉非替尼联合放化疗对EGFR突变型非小细胞肺癌患者的效果。方法:回顾性分析2019年1月至2020年1月该院收治的74例EGFR突变型NSCLC患者的临床资料,按照治疗方法不同将其分为对照组与观察组各37例。对照组采用多西他赛、顺铂化疗联合放疗,观察组在对照组基础上联合吉非替尼片治疗。比较两组临床疗效、不良反应发生率、肿瘤标志物[胸苷激酶1(TK1)、基质金属蛋白酶-9(MMP-9)、组织抑制金属蛋白酶-1(TIMP-1)]水平、生存率。结果:观察组疾病控制率为81.08%,高于对照组的59.46%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P<0.05);治疗后,两组TK1、MMP-9、TIMP-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组6个月生存率比较,差异无统计学意义(P>0.05);观察组1年、1.5年、2年生存率均高于对照组,差异有统计学意义(P<0.05)。结论:吉非替尼联合放疗与多西他赛、顺铂化疗用于EGFR突变型NSCLC患者可提高DCR和远期生存率,降低肿瘤标志物水平,其效果优于多西他赛、顺铂化疗联合放疗。

Objective:To observe effects of Gefitinib combined with chemoradiotherapy on patients with EGFR mutant non-small cell lung cancer.Methods:The clinical data of 74 patients with NSCLC admitted to the hospital from January 2019 to January 2020 were retrospectively analyzed.They were divided into control group and observation group according to different treatment methods,37 cases in each.The control group was treated with Docetaxel and Cisplatin chemotherapy combined with radiotherapy,while the observation group was treated with Gefitinib tablets on the basis of that of the control group.The clinical efficacy,the incidence of adverse reactions,the disease-related indicator levels[thymidine kinase 1(TK1),matrix metalloproteinase-9(MMP-9),tissue inhibitor of metalloproteinase-1(TIMP-1)],and the survival rate were compared between the two groups.Results:The disease control rate of the observation group was 81.08%,which was higher than 59.46%of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P<0.05).After the treatment,the levels of TK1,MMP-9 and TIMP-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in 6-month survival rate between the two groups(P>0.05).The 1-year,1.5-year and 2-year survival rates of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:Gefitinib combined with radiotherapy and Docetaxel and Cisplatin chemotherapy in the treatment of the EGFR mutant NSCLC patients can improve the DCR and the long-term survival rate,and reduce the levels of disease-related indicators.Moreover,it is superior to Docetaxel,Cisplatin chemotherapy combined with rad iotherapy.